Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
International Stem CellISCO -15.69%30 Net Debt Paydown Yield % is 17.90% as of Jul. 19, 2026, which is 396% above its 10-year median of 3.61. GuruFocus rates ISCO with a GF Score™ of 30/100 and a GF Value™ of $0.13 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,163 Biotechnology companies, International Stem Cell ranks better than 94.58% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, International Stem Cell's Net Debt Paydown Yield % was 17.90%.
International Stem Cell (OTCPK:ISCO) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
International Stem Cell Net Debt Paydown Yield % Related Terms
International Stem Cell Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for International Stem Cell's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
International Stem Cell Net Debt Paydown Yield % Chart
ISCO vs ZVSA, AXIM, HEPA: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, International Stem Cell's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
International Stem Cell Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, International Stem Cell's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where International Stem Cell's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 17.90% mean?
International Stem Cell (ISCO) has a Net Debt Paydown Yield % of 17.90% as of Jul. 19, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on International Stem Cell and its competitors. This is 396% above median its historical median of 3.61. According to the industry distribution chart, International Stem Cell ranks #63 out of 1163 companies in the Biotechnology industry, placing it in the top 5.4%.
Is International Stem Cell's Net Debt Paydown Yield % too high?
International Stem Cell's current Net Debt Paydown Yield % of 17.90% is 396% above median its 10-year median of 3.61. The Biotechnology industry median Net Debt Paydown Yield % is 0.03. International Stem Cell's value of 17.90% is 59566.7% above this industry median. Based on the distribution chart, International Stem Cell ranks #63 out of 1163 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, International Stem Cell has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does International Stem Cell's Net Debt Paydown Yield % compare to ZVSA and AXIM?
According to the Biotechnology industry distribution chart, International Stem Cell ranks #63 out of 1163 companies for Net Debt Paydown Yield %. This places International Stem Cell in the top 5% of its industry — outperforming the majority of peers. The industry median Net Debt Paydown Yield % is 0.03. International Stem Cell's value of 17.90% is 59566.7% above this benchmark. While the company's 10-year median is 3.61 vs. the industry median of 0.03, International Stem Cell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.03, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. International Stem Cell's current Net Debt Paydown Yield % of 17.90% is 59566.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on International Stem Cell and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. International Stem Cell's current Net Debt Paydown Yield % is 17.90%, which is 396% above median its own 10-year median of 3.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is International Stem Cell stock overvalued right now?
Based on GuruFocus' analysis, International Stem Cell (ISCO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.18 — trading 38.5% above its estimated fair value. The current Net Debt Paydown Yield % is 17.90%, which is 396% above median its 10-year median of 3.61 and 59566.7% above the Biotechnology industry median of 0.03. International Stem Cell's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For International Stem Cell (ISCO), the current Net Debt Paydown Yield % is 17.90% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is International Stem Cell (ISCO) Overvalued in 2026?
Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued.
The current stock price of $0.18 is trading 38.5% above its estimated GF Value™ of $0.13.
GuruFocus considers International Stem Cell to be Significantly Overvalued.
Key valuation signals for ISCO:
Net Debt Paydown Yield %: 17.90% (396% above median its 10-year median of 3.61)
GF Value™: $0.13 vs. price of $0.18 (38.5% above fair value)
Industry Position: 59566.7% above the Biotechnology median (#63 of 1163)
No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
30GF Score
Get the complete analysis for ISCO
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISCO has been successfully added to your 
